Determinants of use of intermittent preventive treatment of malaria in pregnancy: Jinja, Uganda

listen audio

Study Justification:
This study aimed to identify the determinants of preventive use of sulfadoxine/pyrimethamine (SP) for intermittent preventive therapy (IPTp) during pregnancy in Jinja, Uganda. The study was motivated by the association between maternal malaria and adverse pregnancy outcomes, and the recommendation of IPTp-SP as a means of preventing malaria during pregnancy. The study sought to understand the factors influencing the use of IPTp-SP and to identify missed opportunities for its administration.
Highlights:
– The study found that the use of IPTp-SP in Uganda was far below target levels.
– Women were more likely to take SP for IPTp if it was offered during antenatal care (ANC) visits.
– Missed opportunities to administer IPTp-SP during ANC were common, indicating the need for provider-level improvements.
Recommendations:
– Increase the availability and accessibility of SP for IPTp during ANC visits.
– Implement consistent implementation of directly observed therapy (DOT) for IPTp-SP.
– Improve provider knowledge and adherence to the Ugandan guidelines for IPTp-SP administration.
– Strengthen ANC services to ensure that all pregnant women have the opportunity to receive a full two-dose course of IPTp-SP.
Key Role Players:
– Ministry of Health: Responsible for implementing and overseeing the recommendations at a national level.
– Health facility administrators: Responsible for ensuring the availability of SP and the implementation of IPTp-SP guidelines at health facilities.
– ANC providers: Responsible for offering and administering IPTp-SP during ANC visits.
– Community health workers: Responsible for educating pregnant women about the importance of IPTp-SP and encouraging its use.
Cost Items for Planning:
– Procurement of SP: Budget for the purchase and distribution of SP to health facilities.
– Training and capacity building: Budget for training ANC providers on the administration of IPTp-SP and adherence to guidelines.
– Monitoring and evaluation: Budget for monitoring the implementation of IPTp-SP and evaluating its impact on malaria prevention during pregnancy.
– Community education and awareness: Budget for community health workers to conduct outreach activities and educate pregnant women about the benefits of IPTp-SP.
Please note that the cost items provided are general categories and not actual cost estimates.

The strength of evidence for this abstract is 7 out of 10.
The evidence in the abstract is moderately strong. The study utilized a population-based random sample of 500 women in Jinja, Uganda, which increases the generalizability of the findings. The study identified determinants of preventive use of sulfadoxine/pyrimethamine (SP) during pregnancy and characterized missed opportunities for SP administration. However, the study design was cross-sectional, which limits the ability to establish causality. To improve the evidence, future research could consider a longitudinal design to better understand the factors influencing the use of intermittent preventive therapy (IPTp) for malaria in pregnancy.

Background: Maternal malaria is associated with serious adverse pregnancy outcomes. One recommended means of preventing malaria during pregnancy is intermittent preventive therapy (IPTp) with sulfadoxine/pyrimethamine (SP). We sought to identify determinants of preventive use of SP during pregnancy among recently pregnant women in Uganda. Additionally, we characterized the timing of and indications for the administration of SP at antenatal care (ANC) visits and missed opportunities for SP administration. Methodology/Principal Findings: Utilizing a population-based random sample, we interviewed 500 women living in Jinja, Uganda who had been pregnant in the past year. Thirty-eight percent (192/500) of women received SP for the treatment of malaria and were excluded from the analysis of IPTp-SP. Of the remaining women, 275 (89.3%) reported at least two ANC visits after the first trimester and had an opportunity to receive IPTp-SP according to the Ugandan guidelines, but only 86 (31.3%) of these women received a full two-dose course of IPTp. The remaining 189 (68.7%) women missed one or more doses of IPTp-SP. Among the 168 women that were offered IPTp, 164 (97.6%) of them took the dose of SP. Conclusions/Significance: Use of IPTp in Uganda was found to be far below target levels. Our results suggest that women will take SP for IPTp if it is offered during an ANC visit. Missed opportunities to administer IPTp-SP during ANC were common in our study, suggesting provider-level improvements are needed. © 2010 Sangaré et al.

Between November, 2008 and January, 2009 a simple random sample of 500 female residents of Kibibi and Namizi parishes in Budondo-sub county of Jinja District, Uganda was invited to participate in a home-based interview to ascertain use of ITNs and SP during pregnancy, as well as possible factors associated with use. Interviews were conducted using a structured pre-tested questionnaire adapted from the conceptual framework proposed by Ribera et al. [20]. Women between the ages of 15 and 49 years who had a pregnancy within the past 12 months that lasted until at least the third trimester, regardless of pregnancy outcome, were eligible to participate. Due to the cross-sectional design of the study, current pregnancies were excluded to ensure equal opportunity among all participants to have received IPTp during their most recent pregnancy. Budondo-sub county of Jinja District was selected as the field site based on the availability of a recently completed census in November 2008, allowing for a population-based simple random sample to be selected. Namizi and Kibibi parishes are comprised of 16 rural and peri-urban villages, with a combined population of 21,681, of whom 4,654 were females aged 15–49 years, and 867 of these women reported having been pregnant in the previous 12 months. Jinja district is a peri-urban area where malaria is considered meso-endemic, with a relatively low transmission intensity; the average annual entomological inoculation rate is 6 infective bites per person per year [21]. Each parish has one public health center; Kibibi has a level II facility and Namizi a level IV facility. The administration policy of IPTp and the frequency of stock-outs of SP at the study clinics were assessed prior to the start of the study. Stock-outs of SP during the study period were uncommon (Namizi and Kibibi health centers, personal communication). While the Ugandan guidelines specify IPTp with SP should be taken as directly observed therapy (DOT), this is not consistently implemented in the study clinics due to lack of access to clean water and cups. For each ANC visit the woman attended, we ascertained if SP was offered or not and categorized her experience as 1) having received SP; 2) out of stock of SP, the woman was told to buy it on her own or return to ANC later to receive it; 3) asked to buy SP from the ANC; 4) the ANC never mentioned SP, or 5) SP was offered, but the woman declined to use it. To facilitate recall, a pregnancy history calendar was generated for each woman and used to record episodes of self-reported malaria, any use of SP or other antimalarials during pregnancy, and ANC visits. Additionally, women were shown photographs of SP packaging and the corresponding tablets for the most common formulations of SP available in the area. Self-reported SP use was compared with SP administration as recorded on antenatal cards for the subset of women who had retained the cards. IPTp with SP was defined as a complete 2-dose course of SP administered after the first trimester [9], [22], [23], [24], [25], if the participant believed the SP was used for the prevention of malaria. The analysis of IPTp was restricted to those participants with at least two qualifying ANC visits after the first trimester who had the opportunity to receive a complete course of IPTp. The indication for the use of SP (treatment or prevention) was based on self-report from the woman by asking her if she believed she was sick with malaria for each of the doses of SP that she received. Women who reported receiving SP for the treatment of malaria symptoms were excluded from the analysis of IPTp-SP for the following reasons: 1) determinants of use of treatment doses among women with symptoms suggestive of malaria are likely to be different than those of preventive doses among asymptomatic women; and 2) women who received a therapeutic dose of SP administered in concordance with the IPTp schedule would be unlikely to receive the recommended two or more preventive doses of SP. The Ugandan IPTp guidelines recommend that SP should not be given: during the first trimester of pregnancy, less than 4 weeks between doses, to women with a history of allergies to sulfa drugs, to women concurrently using cotrimoxazole, or to women with symptomatic malaria [26]. IPTp-SP was categorized as a full course: a complete 2-dose course of IPTp administered after the first trimester; partial course: only 1 dose after the first trimester; or none: a) 0 doses in the after the 1st trimester. Analyses were performed using Stata version 11.0 (College Station, Texas, USA). A 7-point composite variable was generated to summarize each woman’s knowledge of malaria, and a 4-point composite variable summarized her knowledge of SP safety. Principal components analysis was used to calculate the household wealth index, a standardized composite measure combining the cumulative living standard of a household and is based on a household’s ownership of selected assets, such as televisions and bicycles, materials used for housing construction, and types of water access and sanitation facilities [27]. Relative risk regression was used to determine the association between exposures of interest and receipt of a full-course of IPTp-SP [28], [29]. Risk estimates were adjusted for the number of ANC visits, however, small numbers precluded further adjustments. The study was approved by the Makerere University Research and Ethics Committee, the Uganda National Council for Science and Technology, and the University of Washington, Human Subjects Division. All participants provided written informed consent.

Based on the provided information, here are some potential innovations that can be used to improve access to maternal health:

1. Mobile Health (mHealth) Solutions: Develop mobile applications or SMS-based systems to provide pregnant women with information about maternal health, including the importance of intermittent preventive therapy (IPTp) with sulfadoxine/pyrimethamine (SP) for preventing malaria during pregnancy. These solutions can also send reminders for ANC visits and IPTp doses.

2. Community Health Workers: Train and deploy community health workers to educate pregnant women about the benefits of IPTp-SP and ensure its availability at ANC clinics. Community health workers can also conduct home visits to reach women who may not have access to ANC services.

3. Supply Chain Management: Improve the supply chain management of SP and other essential maternal health commodities to ensure consistent availability at ANC clinics. This can involve strengthening coordination between health facilities, district health offices, and pharmaceutical suppliers.

4. Provider Training and Support: Provide training and support to healthcare providers on the proper administration of IPTp-SP and the importance of offering it during ANC visits. This can include refresher trainings, job aids, and supervision to ensure adherence to national guidelines.

5. Health Education Campaigns: Conduct targeted health education campaigns to raise awareness among pregnant women and their families about the benefits of IPTp-SP and the importance of ANC visits. These campaigns can use various communication channels, such as radio, television, community meetings, and posters.

6. Integration of Services: Integrate maternal health services, such as ANC, IPTp-SP administration, and malaria prevention, with other existing healthcare services, such as family planning and immunization. This can improve access and uptake of IPTp-SP by ensuring that pregnant women receive multiple services in one visit.

7. Policy Advocacy: Advocate for policy changes and increased funding to prioritize maternal health and improve access to IPTp-SP. This can involve engaging with policymakers, civil society organizations, and international partners to raise awareness about the importance of maternal health and secure resources for implementation.

It is important to note that these recommendations are based on the information provided and may need to be tailored to the specific context and needs of the target population.
AI Innovations Description
The study mentioned is titled “Determinants of use of intermittent preventive treatment of malaria in pregnancy: Jinja, Uganda” and it focuses on identifying factors that influence the use of intermittent preventive therapy (IPTp) with sulfadoxine/pyrimethamine (SP) during pregnancy in Uganda. The study found that the use of IPTp in Uganda was below target levels, with only 31.3% of women receiving a full two-dose course of IPTp.

Based on the findings of the study, here is a recommendation that can be developed into an innovation to improve access to maternal health:

1. Strengthen provider-level improvements: The study identified missed opportunities to administer IPTp-SP during antenatal care (ANC) visits. To address this, health providers should be trained and equipped to offer IPTp-SP as part of routine ANC services. This includes ensuring that SP is consistently available at ANC clinics and that providers are knowledgeable about the guidelines for IPTp-SP administration.

2. Implement directly observed therapy (DOT) for IPTp: The study found that the Ugandan guidelines recommend IPTp with SP to be taken as DOT, but this is not consistently implemented due to lack of access to clean water and cups. To overcome this barrier, innovative solutions can be explored, such as providing clean water and cups at ANC clinics or developing alternative methods of administering SP that do not require water.

3. Increase awareness and education: The study found that women were more likely to take SP for IPTp if it was offered during an ANC visit. Therefore, it is important to increase awareness among pregnant women about the benefits of IPTp-SP and the importance of attending ANC visits. This can be done through community education campaigns, antenatal education sessions, and the distribution of informational materials.

4. Address stock-outs of SP: The study mentioned that stock-outs of SP during the study period were uncommon. However, it is crucial to ensure a consistent supply of SP at ANC clinics to prevent interruptions in IPTp-SP administration. This can be achieved through effective supply chain management and coordination between health facilities and the national drug procurement system.

By implementing these recommendations, access to maternal health can be improved, and the utilization of IPTp-SP can be increased, leading to better outcomes for pregnant women and their babies.
AI Innovations Methodology
Based on the provided information, here are some innovations that could potentially improve access to maternal health:

1. Mobile Health (mHealth) Solutions: Develop mobile applications or SMS-based systems to provide pregnant women with information and reminders about antenatal care visits, medication schedules, and preventive measures. This can help increase awareness and adherence to recommended interventions.

2. Community Health Workers: Train and deploy community health workers to provide education, counseling, and support to pregnant women in their communities. These workers can help identify and address barriers to accessing maternal health services, such as transportation or financial constraints.

3. Telemedicine: Implement telemedicine services to enable remote consultations between pregnant women and healthcare providers. This can help overcome geographical barriers and improve access to specialized care, especially in rural areas.

4. Maternal Health Vouchers: Introduce voucher programs that provide pregnant women with subsidized or free access to essential maternal health services, including antenatal care, delivery, and postnatal care. This can help reduce financial barriers and increase utilization of these services.

To simulate the impact of these recommendations on improving access to maternal health, a possible methodology could include the following steps:

1. Define the target population: Identify the specific population group (e.g., pregnant women in a particular region) that will be the focus of the simulation.

2. Collect baseline data: Gather data on the current utilization of maternal health services, including antenatal care visits, uptake of preventive interventions, and barriers to access. This can be done through surveys, interviews, or analysis of existing data sources.

3. Develop a simulation model: Create a mathematical or computational model that represents the target population and simulates the impact of the recommended innovations on access to maternal health. The model should consider factors such as population size, demographics, healthcare infrastructure, and the potential reach and effectiveness of each innovation.

4. Define outcome measures: Determine the specific indicators that will be used to assess the impact of the recommendations, such as the percentage increase in antenatal care visits or the reduction in missed opportunities for preventive interventions.

5. Input data and run simulations: Input the baseline data into the simulation model and run multiple simulations to estimate the potential impact of each innovation on the defined outcome measures. This can involve varying parameters, such as the coverage and effectiveness of the interventions, to explore different scenarios.

6. Analyze results: Analyze the simulation results to identify the most promising innovations and their potential impact on improving access to maternal health. This can include comparing the outcomes of different scenarios and conducting sensitivity analyses to assess the robustness of the findings.

7. Communicate findings and recommendations: Present the simulation results in a clear and concise manner, highlighting the potential benefits and limitations of each innovation. Use the findings to inform decision-making and prioritize the implementation of interventions that are likely to have the greatest impact.

It is important to note that the methodology described above is a general framework and can be adapted based on the specific context and available data.

Yabelana ngalokhu:
Facebook
Twitter
LinkedIn
WhatsApp
Email